Why the study?
Neurodegeneration influences blood pressure variations and vascular risk factors impair renal function and cerebral perfusion, prompting study into how pharmacogenetics affect cardiovascular risk measures during ACE inhibitor and statin therapy in Alzheimer's dementia.
Does the pharmacological response of blood pressure and creatinine clearance to ACE inhibitors and statins vary by genetic polymorphisms in patients with Alzheimer's dementia?
Population
193 consecutive patients with Alzheimer's dementia
Comparison
Effects of ACE inhibitors and statins across different genetic polymorphisms and haplotypes
Design
Prospective cohort study
Follow-up
One year
Key result
ACE inhibitors reduced blood pressure in Alzheimer's patients, with carriers of Alu DD, rs1800764-C, or rs4291-AT showing significantly better blood pressure lowering effects.
Authors
Loading...
Genetic variants may modulate ACE inhibitor BP response in Alzheimer's; hypothesis-generating, needs prospective validation before clinical use.
Cohort (n=193)
Single-blind
No
Does the pharmacological response of blood pressure and creatinine clearance to ACE inhibitors and statins vary by genetic polymorphisms in patients with Alzheimer's dementia?
The pharmacological response of blood pressure and creatinine clearance to ACE inhibitors and statins in patients with Alzheimer's dementia may be genetically mediated.
Oliveira et al. (2019) conducted a cohort in Alzheimer's dementia (n=193). ACE inhibitors and statins vs. Non-users was evaluated on Variation in one year of creatinine clearance, systolic and diastolic blood pressure. ACE inhibitors reduced blood pressure in Alzheimer's patients, with carriers of Alu DD, rs1800764-C, or rs4291-AT showing significantly better blood pressure lowering effects.